Hero image of a hypothetical patient with hemophilia A going on a hike with spouse
Factor VIII levels at 43%, 4 days after infusion
patient and scenario
Factor Up

with an established safety profile

, people taking

Zero inhibitors i
What are inhibitors? Over time, the body can develop antibodies against Factor VIII, which can prevent treatment from working. People taking ALTUVIIIO had no inhibitors during the clinical trial.

Zero serious allergic reactions

Although no inhibitors were found, and no serious allergic reactions occurred in clinical studies,
inhibitors and serious allergic reactions are possible with ALTUVIIIO.

In 159 people taking ALTUVIIIO in the XTEND-1 study:

  • 21% of people had headache (33 people)
  • 16% of people had joint pain (26 people)
  • 6% of people had back pain
    (9 people)

In 67 children taking ALTUVIIIO in the ongoing XTEND-Kids study:

  • 1% of children had headache (1 child)

How does ALTUVIIIO fit into your lifestyle?

ALTUVIIIO is the only therapy of its kind that is injected once a week.

Connect With a CoRe Manager

Sanofi Hemophilia Community Relations and Education (CoRe) Managers offer education to people living with hemophilia and their families. CoRe Managers provide information about living with hemophilia and treatment options. Use our handy CoRe Locator to find the CoRe team member nearest you.

Connect with a CoRe Manager

Get Informed. Stay Informed.

Let’s stay in touch. We’ll occasionally send you important information on hemophilia A and ALTUVIIIO.